Potency range labeling represents a shift from precise THC/CBD percentages to ranges that better reflect natural variation in cannabis products. This addresses a fundamental disconnect between regulatory precision and biological reality that affects patient dosing accuracy and expectations.
Village Farms is piloting potency range labeling in Canada, moving away from specific cannabinoid percentages to ranges that account for natural variation in cannabis products. Traditional precise labeling (e.g., 18.5% THC) creates false precision when actual potency can vary significantly within batches due to storage, handling, and plant biology. Range labeling (e.g., 16-20% THC) better represents the actual variability patients encounter while maintaining regulatory compliance and consumer information.
“This is long overdue — we’ve been giving patients false precision for years. When I prescribe cannabis, I always counsel patients that the labeled percentage is approximate, not gospel, because the plant doesn’t read the label.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
FAQ
What is the clinical relevance rating for this cannabis news update?
This update has been assigned CED Clinical Relevance #78 with a “Notable Clinical Interest” classification. This indicates emerging findings or policy developments that healthcare professionals should monitor closely.
What key areas does this cannabis clinical update cover?
The update focuses on four main areas: dosing guidelines, product quality standards, patient education materials, and regulatory developments. These represent critical components of clinical cannabis practice.
Why is this classified as “Notable Clinical Interest”?
This classification suggests the information contains emerging findings or policy developments that could impact clinical practice. Healthcare providers should pay close attention to these developments as they may influence treatment protocols.
What type of healthcare professionals should review this update?
This update is primarily intended for clinicians working with cannabis therapeutics, including physicians, pharmacists, and other healthcare providers involved in medical cannabis programs. The clinical relevance rating indicates it’s particularly important for those actively treating patients with cannabis-based medicines.
How should clinicians use this information in practice?
Clinicians should monitor these developments closely as they may influence dosing decisions, product selection, patient counseling approaches, and compliance with evolving regulations. The information should be integrated into clinical decision-making processes as appropriate.